StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Research analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, February 26th.

Minerva Neurosciences Price Performance

Shares of NERV stock opened at $1.64 on Monday. The stock has a market cap of $11.47 million, a PE ratio of -3.73 and a beta of 0.10. The stock has a 50-day moving average of $2.08 and a 200-day moving average of $2.33. Minerva Neurosciences has a one year low of $1.42 and a one year high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. As a group, research analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC lifted its holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.